Trade Standard BioTools Inc - LAB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0200 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023568% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001346% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.165 |
| Open | 1.105 |
| 1-Year Change | -57.88% |
| Day's Range | 1.065 - 1.105 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 3, 2025 | 1.0650 | -0.0100 | -0.93% | 1.0750 | 1.1050 | 1.0650 |
| Apr 2, 2025 | 1.1650 | 0.1100 | 10.43% | 1.0550 | 1.1750 | 1.0550 |
| Apr 1, 2025 | 1.0850 | 0.0300 | 2.84% | 1.0550 | 1.1550 | 1.0550 |
| Mar 31, 2025 | 1.0750 | -0.0200 | -1.83% | 1.0950 | 1.1250 | 1.0450 |
| Mar 28, 2025 | 1.1250 | 0.0000 | 0.00% | 1.1250 | 1.1250 | 1.0650 |
| Mar 27, 2025 | 1.1250 | -0.0600 | -5.06% | 1.1850 | 1.1950 | 1.1250 |
| Mar 26, 2025 | 1.1850 | 0.0300 | 2.60% | 1.1550 | 1.1850 | 1.1450 |
| Mar 25, 2025 | 1.1550 | 0.0000 | 0.00% | 1.1550 | 1.1650 | 1.1050 |
| Mar 24, 2025 | 1.1350 | -0.0700 | -5.81% | 1.2050 | 1.2450 | 1.1350 |
| Mar 21, 2025 | 1.2050 | 0.0600 | 5.24% | 1.1450 | 1.2150 | 1.1350 |
| Mar 20, 2025 | 1.1550 | 0.0000 | 0.00% | 1.1550 | 1.1750 | 1.1450 |
| Mar 19, 2025 | 1.1750 | 0.0300 | 2.62% | 1.1450 | 1.1950 | 1.1450 |
| Mar 18, 2025 | 1.1550 | -0.0100 | -0.86% | 1.1650 | 1.1650 | 1.1050 |
| Mar 17, 2025 | 1.1550 | 0.0500 | 4.52% | 1.1050 | 1.1650 | 1.1050 |
| Mar 14, 2025 | 1.1250 | 0.0300 | 2.74% | 1.0950 | 1.1450 | 1.0950 |
| Mar 13, 2025 | 1.0950 | -0.0500 | -4.37% | 1.1450 | 1.1550 | 1.0750 |
| Mar 12, 2025 | 1.1350 | -0.0100 | -0.87% | 1.1450 | 1.1750 | 1.0950 |
| Mar 11, 2025 | 1.1250 | 0.0700 | 6.64% | 1.0550 | 1.1450 | 1.0550 |
| Mar 10, 2025 | 1.0750 | -0.0400 | -3.59% | 1.1150 | 1.1250 | 1.0550 |
| Mar 7, 2025 | 1.1550 | 0.0400 | 3.59% | 1.1150 | 1.1550 | 1.0950 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Standard BioTools Inc Company profile
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Fluidigm Corporation revenues decreased 5% to $130.6M. Net loss increased 12% to $59.2M. Revenues reflect Development revenue segment decrease of 71% to $2.6M, Instruments segment decrease of 7% to $42.5M, United States segment decrease of 16% to $60.2M, Asia-Pacific segment decrease of 7% to $24M. Higher net loss reflects Research and development increase of 4% to $37.9M (expense), Selling.
Equity composition
Common Stock $0.001 Par, 2/11, 19,938,754 auth, 19,938,754 issd. Insiders own approx. 11.14%.
| Industry: | Advanced Medical Equipment & Technology (NEC) |
2 Tower Place
Suite 2000
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com